Evotec AG’s multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II development for the treatment of chronic cough, resulting in a €4 million payment to Evotec. The Phase II has been initiated following positive Phase I results under the ongoing Bayer-Evotec endometriosis alliance. The potential to treat patients with a persistent chronic cough was highlighted due to the nature and expression of the target protein being originally e...